Adam J. N

Jun 5, 2024 | dialnet.unirioja.es | Alexander C. Egilman |Aaron S. Kesselheim |Jerry Avorn |Adam J. N

Use of Efficiency Frontiers to Align Prices and Clinical Benefits of Biologic Therapies for Plaque PsoriasisAutores: Alexander C. Egilman, Aaron S. Kesselheim, Jerry Avorn, Adam J. N. Raymakers, Benjamin N. RomeLocalización: JAMA Dermatology, ISSN 2168-6068, Vol. 160, Nº. 4, 2024, págs. 409-416Idioma: inglésEnlacesTexto completoResumenImportance The US lacks a systematic approach for aligning drug prices with clinical benefit, and traditional cost-effectiveness analysis (CEA) faces political obstacles.

Jun 4, 2024 | dialnet.unirioja.es | Aaron S. Kesselheim |Arash Mostaghimi |William B. Feldman |Adam J. N

Estimated Spending on Beremagene Geperpavec for Dystrophic Epidermolysis BullosaAutores: Adam J. N. Raymakers, Aaron S. Kesselheim, Arash Mostaghimi, William B. FeldmanLocalización: JAMA Dermatology, ISSN 2168-6068, Vol. 160, Nº. 3, 2024, págs. 297-302Idioma: inglésEnlacesTexto completoResumenNew gene therapies can offer substantial benefits to patients, particularly those with rare diseases who have few therapeutic options.